ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA MARKET ANALYSIS

Regional Analysis

Global Angioimmunoblastic T-Cell Lymphoma Market – Regional Insights

Among regions, North America holds dominant position in the global angioimmunoblastic t-cell lymphoma market during the forecast period. The major factor contributing in the market growth is majorly owing to high incidence of AITL in the region. For instance, according to the World Health Organization (WHO) 2017 revision, there are 29 distinct subtypes of peripheral T-cell lymphomas (PTCL) out of which the two most common forms are angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) accounting for an incidence of 1,800 and 2,500 cases per year in the U.S.

Asia Pacific is projected to grow with the fastest CAGR in the global angioimmunoblastic t-cell lymphoma market during the forecast period. The growth can be attributed to the extensive research taking place in the region. For instance, at the ESMO Asia Virtual Congress 2020, researchers discussed the treatment strategies for T-cell non-Hodgkin lymphomas (NHLs) by identification of the prevalence the subtypes, patient outcomes and available treatments across several Asian countries. This involved various multinational, multicentre prospective intercontinental registry studies conducted in research institutes situated in China, Indonesia, , Singapore, Taiwan and the Republic of Korea.